
[009a] In an aspect, there is provided the use of a therapeutically effective amound of a compound that inhibits FAK, SRC, and JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C, wherein the compound is




or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a patient,

wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, or ARS-1620, or a pharmaceutically acceptable salt thereof, and

the cancer is colorectal cancer, pancreatic cancer, or lung cancer.

[009b] In another aspect, there is provided the use of a therapeutically effective amount of a compound that inhibits FAK, SRC, and JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C, wherein the compound is



,

in the manufacture of a medicament for the treatment of cancer in a patient,

wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, or ARS-1620, or a pharmaceutically acceptable salt thereof, and

the cancer is colorectal cancer, pancreatic cancer, or lung cancer.

[010] In one example, the disclosure provides a method for treating cancer in a host animal, the method comprising the step of administering to the host animal a therapeutically effective amount of one or more compounds that inhibit FAK, SRC and/or JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C. In some examples, the host animal is a human patient. In some examples, the host animal is a laboratory animal such as a rodent.

[011] In another example, the disclosure provides a method for treating cancer in a host animal, the method comprising the step of administering to the host animal a therapeutically effective amount of a compound that inhibits FAK, SRC, and JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C. In some examples, the host animal is a human patient. In some examples, the host animal is a laboratory animal such as a rodent.

[012] In another example, the disclosure provides one of more compounds that inhibit FAK, SRC and/or JAK2, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.


[013] In another example, the disclosure provides a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.

[014] In another example, the disclosure provides use of one or more compounds that inhibit FAK, SRC and/or JAK2, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament comprising a therapeutically effective amount of the compound, for treating cancer in a patient in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.

[015] In another example, the disclosure provides use of a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament comprising a therapeutically effective amount of the compound, for treating cancer in a patient in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.

What is claimed:

1. Use of a therapeutically effective amound of a compound that inhibits FAK, SRC, and JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C, wherein the compound is



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a patient,

wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, or ARS-1620, or a pharmaceutically acceptable salt thereof, and

the cancer is colorectal cancer, pancreatic cancer, or lung cancer.

2. The use of claim 1, wherein the cancer is pancreatic cancer.

3. The use of claim 1, wherein the cancer is lung cancer.

4. The use of claim 1, wherein the cancer is non-small cell lung cancer.

5. The use of claim 1, wherein the cancer is colorectal cancer.

6. The use of claim 1, wherein the compound that inhibits FAK, SRC, and JAK2 is to be administered at the same time as, before, or after the at least one agent that inhibits KRAS G12C.

7. The use of claim 1, wherein IL-6 secretion from the cancer is decreased.

8. The use of any one of claims 1 to 7, wherein the at least one agent that inhibits KRAS G12C is ARS-1620, or a pharmaceutically acceptable salt thereof.

9. The use of any one of claims 1 to 7, wherein the at least one agent that inhibits KRAS G12C is AMG-510, or a pharmaceutically acceptable salt thereof.

10. The use of any one of claims 1 to 7, wherein the at least one agent that inhibits KRAS G12C is MRTX849, or a pharmaceutically acceptable salt thereof.

11. The use of claim 1, wherein the compound that inhibits FAK, SRC and JAK2 is to be administered at a dose of 0.1 mg to 3 g, or 1 mg to 50 mg, or 50 to 250 mg, or 150 to 500 mg, or 150 to 250 mg, or 250 mg to 1 g, or 100 mg to 2 g, or 500 mg to 2 g, or 500 mg to 1 g, or 100 mg

to 300 mg, or 160 mg; and the at least one agent that inhibits KRAS G12C is to be administered at a dose of 0.1 mg to 3 g, or 1 mg to 50 mg, or 50 to 250 mg, or 150 to 500 mg, or 150 to 250 mg, or 250 mg to 1 g, or 100 mg to 2 g, or 500 mg to 2 g, or 500 mg to 1 g, or 800 mg to 1.5 g, or at least 800 mg, or at least 600 mg, or 960 mg, or 600 mg.


12. The use of claim 1, wherein the compound that inhibits FAK, SRC and JAK2 is to be administered at a dose of 0.1 mg/kg to 1 g/kg, or 0.5 mg/kg to 50 mg/kg, or 0.5 mg/kg to 25 mg/kg, or 1.0 mg/kg to 10 mg/kg, or 1.0 mg/kg to 5 mg/kg, or 0.1 mg/kg to 5 mg/kg, or 0.1 mg/kg to 1 mg/kg, or 0.1 mg/kg to 0.6 mg/kg, or 1.25 mg/kg to 3.75 mg/kg, or 1.0 mg/kg, 2.0 mg/kg, or 3.0 mg/kg, or 4.0 mg/kg and the at least one agent that inhibits KRAS G12C is to be administered at a dose of 0.1 mg/kg to 1 g/kg, or 0.5 mg/kg to 50 mg/kg, or 0.5 mg/kg to 25 mg/kg, or 1.0 mg/kg to 10 mg/kg, or 1.0 mg/kg to 5 mg/kg, or 0.1 mg/kg to 5 mg/kg, or 0.1 mg/kg to 1 mg/kg, or 0.1 mg/kg to 0.6 mg/kg, or 1.25 mg/kg to 3.75 mg/kg, or 1.0 mg/kg, 2.0 mg/kg, or 3.0 mg/kg, or 4.0 mg/kg.

13. The use according to claim 1, wherein the patient is a human patient in need of such treatment who has not received a prior treatment.

14. The use according to claim 1, wherein the patient is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies.

15. The use according to claim 1, wherein the patient is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies, and developed an acquired resistance to the treatment, and/or developed bypass resistance to the treatment, and/or developed bypass resistance to the treatment regulated by FAK, SRC or JAK2.

16. Use of a therapeutically effective amount of a compound that inhibits FAK, SRC, and JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C, wherein the compound is



,

in the manufacture of a medicament for the treatment of cancer in a patient,
wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, or ARS-1620, or a pharmaceutically acceptable salt thereof, and
the cancer is colorectal cancer, pancreatic cancer, or lung cancer.

17. The use of claim 16, wherein the cancer is pancreatic cancer.

18. The use of claim 16, wherein the cancer is lung cancer.

19. The use of claim 16, wherein the cancer is non-small cell lung cancer.

20. The use of claim 16, wherein the cancer is colorectal cancer.

21. The use of claim 16, wherein the compound that inhibits FAK, SRC, and JAK2 is to be administered at the same time as, before, or after the at least one agent that inhibits KRAS G12C.

22. The use of claim 16, wherein IL-6 secretion from the cancer is decreased.

23. The use of any one of claims 16 to 22, wherein the at least one agent that inhibits KRAS G12C is ARS-1620, or a pharmaceutically acceptable salt thereof.

24. The use of any one of claims 16 to 22, wherein the at least one agent that inhibits KRAS G12C is AMG-510, or a pharmaceutically acceptable salt thereof.

25. The use of any one of claims 16 to 22, wherein the at least one agent that inhibits KRAS G12C is MRTX849, or a pharmaceutically acceptable salt thereof.

26. The use of claim 16, wherein the compound that inhibits FAK, SRC and JAK2 is to be administered at a dose of 0.1 mg to 3 g, or 1 mg to 50 mg, or 50 to 250 mg, or 150 to 500 mg, or 150 to 250 mg, or 250 mg to 1 g, or 100 mg to 2 g, or 500 mg to 2 g, or 500 mg to 1 g, or 100 mg to 300 mg, or 160 mg; and the at least one agent that inhibits KRAS G12C is to be administered at a dose of 0.1 mg to 3 g, or 1 mg to 50 mg, or 50 to 250 mg, or 150 to 500 mg, or 150 to 250 mg, or 250 mg to 1 g, or 100 mg to 2 g, or 500 mg to 2 g, or 500 mg to 1 g, or 800 mg to 1.5 g, or at least 800 mg, or at least 600 mg, or 960 mg, or 600 mg.

27. The use of claim 16, wherein the compound that inhibits FAK, SRC and JAK2 is to be administered at a dose of 0.1 mg/kg to 1 g/kg, or 0.5 mg/kg to 50 mg/kg, or 0.5 mg/kg to 25 mg/kg, or 1.0 mg/kg to 10 mg/kg, or 1.0 mg/kg to 5 mg/kg, or 0.1 mg/kg to 5 mg/kg, or 0.1 mg/kg to 1 mg/kg, or 0.1 mg/kg to 0.6 mg/kg, or 1.25 mg/kg to 3.75 mg/kg, or 1.0 mg/kg, 2.0 mg/kg, or 3.0 mg/kg, or 4.0 mg/kg and the at least one agent that inhibits KRAS G12C is to be administered at a dose of 0.1 mg/kg to 1 g/kg, or 0.5 mg/kg to 50 mg/kg, or 0.5 mg/kg to 25 mg/kg, or 1.0 mg/kg to about 10 mg/kg, or 1.0 mg/kg to 5 mg/kg, or 0.1 mg/kg to 5 mg/kg, or

0.1 mg/kg to 1 mg/kg, or 0.1 mg/kg to 0.6 mg/kg, or 1.25 mg/kg to 3.75 mg/kg, or 1.0 mg/kg, 2.0 mg/kg, or 3.0 mg/kg, or 4.0 mg/kg.

28. The use of claim 16, wherein the patient is a human patient in need of such treatment who has not received a prior treatment.

29. The use of claim 16, wherein the patient is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies.

30. The use of claim 16, wherein the patient is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies, and developed an acquired resistance to the treatment, and/or developed bypass resistance to the treatment, and/or developed bypass resistance to the treatment regulated by FAK, SRC or JAK2.